The company submitted data showing A400's efficacy in patients with advanced RET fusion-positive NSCLC in the first- or later-line treatment.

The firm's lead candidate, EN-374 for X-linked chronic granulomatous disease, is being evaluated in a Phase I/II trial.

The agency held a meeting to gather drugmakers' perspectives as it considers a draft guidance on how previously generated ...

The firm has randomized participants in the REGENERATE-PD study of AB-1005 in the UK and Poland, with plans to expand to Germany next.

Advanced ER-positive breast cancer patients on giredestrant and Afinitor had better progression-free survival versus standard therapy in the evERA trial.

Regulators in the UK also approved the IDH1/2 inhibitor last week, making it the first precision targeted treatment in Europe for this post-surgery setting.

A real-world study showed that patients who had the classical subtype based on an RNA signature had better survival on ...

A team from Shriners Children's and Washington University in St. Louis are investigating a new method for personalizing ...

Investigators have used base editing to create a treatment for multisystemic smooth muscle dysfunction syndrome, which has ...

After the deal closes, Biogen will be in charge of developing and selling Alcyone's ThecaFlex DRx implantable subcutaneous port and catheter device.

The firm is restructuring to extend its cash runway and focus resources on clinical programs, including a Phase I CAR T-cell trial in kidney cancer.

The company has already been testing the autologous cell therapy, LioCyx-M004, in patients with certain liver cancers.